Journal of the American Academy of Child & Adolescent Psychiatry
New ResearchMedication and Parent Training in Children With Pervasive Developmental Disorders and Serious Behavior Problems: Results From a Randomized Clinical Trial
Section snippets
Method
Additional information regarding the background, feasibility, and methods for this study are described in detail elsewhere.12, 18, 34 The institutional review boards of the clinical sites approved this investigation, and the parents or legal guardians of all child participants provided written informed consent.
Subject Characteristics
As shown in Figure 1, 199 potential participants were screened, and 124 (62%) were randomized to this trial. Of the 48 ineligible to participate, 18 (38%) did not have a PDD, 14 (29%) had ABC Irritability scores less than 18 (two children failed both criteria), and five (10%) had other DSM diagnoses that were exclusionary. The remaining screen failures were excluded for a multitude of reasons (across five inclusion/exclusion criteria) or because of a threat to the protocol (e.g., already
Discussion
To our knowledge, this is the first randomized controlled trial to examine the combination of PT and medication in children with PDDs. The primary outcome variable, HSQ score, showed additive benefit (p = .006) with COMB, with a between-groups effect size of 0.34 at week 24. This added effect of PT was detectable over and above the large treatment effect of medication alone. Combined treatment also showed added benefit in reducing the serious behavioral problems that brought the children into
References (53)
- et al.
Psychopathology and intellectual disability: the Australian Child to Adult Longitudinal Study
- et al.
Risperidone and adaptive behavior in children with autism
J Am Acad Child Adolesc Psychiatry
(2006) - et al.
Errorless academic compliance training: improving generalized cooperation with parental request in children with autism
J Am Acad Child Adolesc Psychiatry
(2004) - et al.
Skill acquisition in parents of children with developmental disabilities. Interaction between skill type and instructional format
Res Dev Disabil
(2000) - et al.
Parent-directed, intensive early intervention for children with pervasive developmental disorder
Res Dev Disabil
(2000) - et al.
Effects on parental mental health of an education and skills training program for parents of young children with autism: a randomized controlled trial
J Am Acad Child Adolesc Psychiatry
(2006) - et al.
The Children's Yale-Brown Obsessive-Compulsive Scale modified for pervasive developmental disorders
J Am Acad Child Adolesc Psychiatry
(2006) - et al.
Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment
J Am Acad Child Adolesc Psychiatry
(2001) - et al.
A comparison of cognitive-behavioral therapy, sertraline, and their combination for adolescent depression
J Am Acad Child Adolesc Psychiatry
(2006) Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision
(2000)
Behavioral and emotional problems in young people with pervasive developmental disorders: relative prevalence, effects of subject characteristics, and empirical classification
J Autism Dev Disord
Comparison of DSMIV symptoms in elementary school-aged children with PDD versus clinic and community samples
Autism
Medication patterns in patients with autism: Temporal, regional, and demographic influences
J Child Adolesc Psychopharmacol
Treatment incidence and patterns in children and adolescents with autism spectrum disorders
J Child Adolesc Psycho-pharmacol
Medication use among children with autism spectrum disorders
J Child Adolesc Psychopharmacol
Risperidone in children with autism and serious behavior problems
N Engl J Med
Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders
Pediatrics
Risperidone treatment of autistic disorder: longer term benefits and blinded discontinuation after six months
Am J Psychiatry
Testing the combined effects of medication and behavioral intervention in children with pervasive developmental disorders
J Autism Dev Disord
LEAP preschool
A demonstration of behavioral support for young children with autism
J Posit Behav Interv
Pivotal response intervention II: Preliminary long-term outcome data
J Assoc Pers Sev Handicaps
The Douglass Developmental Disabilities Center: two models of service delivery
Autistic disorder. Treatment of childhood disorders
Development of a parent training program for children with pervasive developmental disorders
Behav Interv
Increasing autistic children's daily spontaneous speech
J Appl Behav Anal
Cited by (229)
Psychopharmacology Management in Autism Spectrum Disorder
2024, Pediatric Clinics of North AmericaPharmacological Therapies in Children and Adolescents
2022, Comprehensive Clinical Psychology, Second EditionDirect observation in a large-scale randomized trial of parent training in children with autism spectrum disorder and disruptive behavior
2021, Research in Autism Spectrum DisordersParenting Practices and Externalizing Behaviors in Autistic Children: A Systematic Literature Review
2024, Clinical Child and Family Psychology Review
This article was reviewed under and accepted by Deputy Editor John T. Walkup, M.D.
This work was funded by the National Institute of Mental Health by the following RUPP grants: Ohio State University, U10MH66768; Indiana University, U10MH66766; and Yale University, U10MH66764. Johnson & Johnson Pharmaceutical Research & Development provided active risperidone for the study.
National Institutes of Health participation is reflected above in individual authors' contributions. The views expressed in this article are those of the authors and do not necessarily reflect the official position of the National Institute of Mental Health, the National Institutes of Health, or any other part of the U.S. Department of Health and Human Services.
The authors acknowledge the contributions of: Ohio State University: Amanda Cook, B.A.; Kristina Humphries, M.S.; Lorelai Ark, M.A.; Susan Thompson, M.S.N., C.P.N.P., Indiana University: Jon T. Diener, B.S.; Kelly A. Ernsperger, L.C.S.W.; Joy M. Fairbanks, M.S.; Jennifer E. Mullett, R.N.; Marianna R. Zaphiriou, B.A. Yale University: Mary Ellen Pachler. National Institute of Mental Health: William R. Harlan, M.D., NIH National Library of Medicine; for support as scientific advisors: Andrew C. Leon, Ph.D., Weill Medical College of Cornell University; Jose Alvir, Dr.P.H., Pfizer, Inc.; C.T. Gordon, M.D., private practice, Rockville, MD; Sandra Harris, Ph.D., Rutgers University, State University of New Jersey; Henrietta Leonard, M.D., Brown University; Susan Swedo, M.D., NIMH Intramural Research Program; Richard Todd, Ph.D., M.D., Washington University School of Medicine.
Clinical trial registration information —RUPP PI PDD: Drug and Behavioral Therapy for Children With Pervasive Developmental Disorders. URL: http://clinicaltrials.gov. Unique identifier: NCT00080145.